SCHEMBL21547540

SCHEMBL21547540

CC1=CCCC(Oc2ccccc2)=C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 6/20 0.39
TSHR P16473 1/20 0.39
NPC1 O15118 1/20 0.33
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR1H2 P55055 1/20 0.32
BAX Q07812 1/20 0.32
MAOA P21397 1/20 0.32
CA4 P22748 1/20 0.32
LMNA P02545 1/20 0.32
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30
MAPT P10636 1/20 0.30
CYP2C9 P11712 1/20 0.30
HPGD P15428 1/20 0.30
MAPK1 P28482 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13624036 0.80 KCNA3 (0.42) LTA4HMAOAMAPT
SCHEMBL12825534 0.71
SCHEMBL10942010 0.68 LTA4H (0.46) LTA4HTSHRHTTNR1H2BAX
SCHEMBL12332681 0.68 LTA4H (0.58) LTA4HTSHRNR1H2BAXMAOA
SCHEMBL14649909 0.68 TEAD4 (0.37) HTTSMN1; SMN2MEN1MAPTCYP2C9
SCHEMBL7311628 0.67 LTA4H (0.44) LTA4HTSHRNR1H2BAXMAOA
SCHEMBL18654448 0.65
SCHEMBL19299976 0.65 LTA4H (0.42) LTA4HTSHRNR1H2BAXMAOA
SCHEMBL21305456 0.63 CALM1 (0.39) LTA4HTSHRNPC1NR1H2MAOA
SCHEMBL22003260 0.63 HPGD (0.41) TSHRNPC1HTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117285464-A Roflumilast intermediate compound and preparation method and application thereof 山东新时代药业有限公司 2023-12-26 CN disclosed
EP-3110418-B1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2019-11-06 EP disclosed